Senseonics Launches One-Year Eversense 365 CGM In Sweden, Germany, Spain, Italy
Senseonics launched its Eversense 365 one-year implantable CGM in Sweden on April 24, with Germany, Spain and Italy rollouts slated in coming weeks under its phased European rollout. The device doubles sensor lifespan from six months to 12 months and cuts calibration frequency to once weekly.
1. European Rollout Strategy
Eversense 365 received CE Mark approval in January and launched in Sweden on April 24, with Germany, Spain and Italy rollouts scheduled over the coming weeks. This phased approach targets major European diabetes centers to build on clinical adoption and streamline supply chain logistics.
2. Technical Advancements
The Eversense 365 system doubles sensor lifespan from six months to a full year and reduces calibrations from once daily to once weekly. Its removable smart transmitter minimizes CGM waste by allowing users to reattach the device without replacing the sensor.
3. Market Expansion Impact
The European launch adds over 30 million patients to Senseonics’ total addressable market and supports its shift to an end-to-end commercial organization. This follows the U.S. FDA approval in September 2024 and nationwide launch in October, driving established revenue growth.
4. Patient Outcomes and Evidence
Real-world evidence over a full year shows sustained accuracy, minimal false alerts and improved A1C levels, enhancing patient confidence in diabetes management. The one-year monitoring capability reduces device interruptions and supports better time-in-range outcomes.